



ENGOT model A  
Sponsor AGO Study Group



\* Recommended platinum-based chemotherapy regimens:  
- carboplatin/paclitaxel  
- carboplatin/gemcitabine  
- carboplatin/pegliposomal doxorubicin  
*-or other platinum combinations in prospective trials*



**AGO-OVAR OP.4**  
**AGO-DESKTOP OVAR III**  
**ENGOT-ov20**



**Primary objective:**

- Overall survival (after 244 OS events observed)

**Secondary objectives:**

- Progression-free survival
- Quality of Life
- Rate of complete resection as prognostic factor
- Complication rates of surgery
- Exploratory analysis of surgical characteristics and chemotherapy, prognostic factors

**Status September 2017**

153 of 244 OS events observed

First Patient in	14-Jul-2010
Last Patient in	25-Mar-2015
Enrolment period	58 months
Planned period	36 months
OS analyses	final ~ 2019

**Interim analysis presented at ASCO 2017**

**OS follow-up ongoing**